Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
2020年1月28日 - 10:02PM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced an update to its Parkinson’s Disease program SLS-007.
Seelos is to begin an in-vivo study delivering
SLS-007 by an Adeno-Associated Virus (AAV) vector making the
program Seelos’ second gene therapy approach for Parkinson’s
Disease (PD). Seelos is currently producing the viral vectors
and preparing animals for this study. Data to determine delivery
and target engagement is expected in the second half of this
year.
“Identifying the AAV vector as the optimal route
of systemic administration of SLS-007 may ultimately yield a
convenient one-time delivery of the peptides,” said Raj Mehra,
Ph.D., Chairman and CEO of Seelos. “This is a novel method of viral
delivery that has been a collaboration between our R&D team and
key opinion leaders that, if successful, could be a major
advancement in the field.”
“The study will include measurements of several
key biomarkers that will assess the extent of alpha-synuclein
(α-synuclein) aggregates expression in key target areas of the
brain, such as the forebrain and the substantia nigra. These
outcomes will help determine key target engagement and set the
stage for our next steps with the program,” added Tim Whitaker, MD,
Head of R&D at Seelos.
Seelos is also developing SLS-004, which is an
all-in-one lentiviral vector gene therapy program that targets the
SNCA gene that encodes for the production of α-synuclein.
About SLS-007
SLS-007 is a family of rationally designed
peptidic inhibitors that target the NACore (non-amyloid component
core) of α-synuclein to inhibit protein aggregation in patients
with PD. The overexpression of α-synuclein leads to the formation
of α-synuclein aggregates which comprise Lewy bodies and neurites
which are the hallmarks of the pathogenesis of PD. Recent in-vitro
and cell culture research have shown that SLS-007 has the potential
to stop the propagation and seeding of α-synuclein aggregates. The
goal of the in-vivo animal study will be to establish
pharmacokinetic (PK) and pharmacodynamic (PD) profiles and
target engagement parameters of SLS-007.
Forward-Looking Statements
Statements made in this press release, which are
not historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, among
others, those regarding the use of the Adeno-Associated Virus
vector for systemic administration of SLS-007 and the potential
success of this method of viral delivery, expectations regarding
the timing for receiving data from the in-vivo animal study of
SLS-007 to establish pharmacokinetic and pharmacodynamics profiles
and target engagement parameters of SLS-007 and expectations
regarding the results of the in-vivo animal study of SLS-007. These
statements are based on Seelos' current expectations and beliefs
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Risks associated with Seelos'
business include, but are not limited to, the risk of not
successfully executing its clinical studies and not gaining
marketing approvals for its product candidates, the risks
associated with the implementation of a new business strategy, the
risks related to raising capital to fund its development plans and
ongoing operations, as well as other factors expressed in Seelos'
periodic filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, even if subsequently made
available by us on our website or otherwise. We do not undertake
any obligation to update, amend or clarify these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws.
Contact Information:
Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.comhttps://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024